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Mice are used as models for western equine encephalitis virus (WEEV) infection, but high mortality is generally only seen with intracranial or
intranasal challenge, while peripheral inoculation results in approximately 50% mortality and is not dose-dependent. Hamsters were therefore
studied as a model for WEEV infection. Hamsters were highly sensitive to intraperitoneal (i.p.) infection with WEEV. Disease progression was
rapid, and virus titers in serum, brain, liver, and kidney of infected hamsters peaked between 2 and 4 days post-virus inoculation (dpi). Foci of
virus infection were detected in neurons of the cerebral cortex and midbrain. Pre-treatment i.p. with either interferon alfacon-1 (5 μg/kg/day) or
with Ampligen® (3.2 mg/kg/day) resulted in complete survival, reduced brain titers, and improved weight gain. This model of WEEV infection in
hamsters appears to serve as a suitable model for the evaluation of potential therapeutic agents for the treatment of WEE disease.
© 2006 Elsevier Inc. All rights reserved.Keywords: Western equine encephalitis virus; Alphavirus; Interferon; Infergen; Ampligen®; Antiviral; Hamster; Treatment; ModeIntroduction
Western equine encephalitis virus (WEEV) is a pathogen of
human concern that is endemic to the Americas, and periodic
outbreaks cause morbidity and mortality in different species
including equines and humans (Calisher, 1994). While human
outbreaks are infrequent, the case fatality rate may be as high as
15%, and the disease is generally more severe in infants that are
less than 1 year old. It is important that therapies be developed
for the treatment of this disease (Sidwell and Smee, 2003).
Mice have been used as models for WEEV infection,
including antiviral and virulence studies (Bianchi et al., 1993;
Hunt and Roehrig, 1985; Monath et al., 1978; Nagata et al.,
2005, 2006; Takehara, 1977). Inoculation through peripheral
routes, including intraperitoneal (i.p.), intrademal, and sub-
cutaneous, generally results in approximately 50% mortality,
and infection through these routes is not dose-dependent as⁎ Corresponding author. Fax: +1 435 797 3959.
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doi:10.1016/j.virol.2006.10.031compared with more lethal intracranial and intranasal (i.n.)
inoculation (Hardy et al., 1997; Liu et al., 1970). In a mouse
pathogenesis study, subcutaneous infection of 1- to 2-day-old
mice resulted in high mortality, but pathologic changes were
limited to muscle, cartilage, and bone marrow, while infection
3-week-old mice resulted in diffuse meningoencephalitis and
changes in heart, lung, kidney, liver, and brown fat (Aguilar,
1970). Previous work has shown that hamsters serve as suitable
models for disease caused by WEEV, and high mortality and
lesions of encephalitis were observed in adult hamsters
inoculated with a virulent strain of WEEV (Zlotnick et al.,
1972). Hamsters have been used as models for WEEV infection
for immune clearance and virulence studies and are susceptible
to WEEV disease (Jahrling, 1976; Jahrling et al., 1983).
Interferon alfacon-1 is a consensus-type interferon that has
been efficacious in the clinical treatment of hepatitis C virus
(HCV) infections in human patients (Melian and Plosker, 2001;
Sjogren et al., 2005; Yasuda and Miyata, 2002), as well as in
treatment of various viral diseases and cancer in experimental
animal models or cell culture models (Hisaka et al., 2004;
Fig. 1. Time-course of WEEV titer in various tissues from infected hamsters
(***P<0.001, **P<0.01, *P<0.05 as compared with sham-infected).
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2000). This cytokine works well in humans as well as in
hamsters against different viral diseases (Balan et al., 2006;
Gowen et al., 2005; Morrey et al., 2004a). Ampligen® [polyI:
polyC12U] is a double-stranded RNA, which elicits an antiviral
response at least through the activation of cellular RNase-L and
the production of interferon (Anon, 2004). Ampligen® has been
shown to have activity against many different viruses and other
diseases in vivo (Essey et al., 2001; Leyssen et al., 2003;
Morrey et al., 2004a; Wild et al., 1996). This compound has also
been shown to be efficacious in hamster models of viral disease
(Gowen et al., 2005; Morrey et al., 2004a; Smee et al., 1993).
The purposes of these studies were to characterize the
WEEV infection of hamsters for use as a model for encephalitic
alphavirus infection and to then use the model to evaluate the
efficacy of pre-exposure treatment of animals with interferon
alfacon-1 and Ampligen®. Such studies with known antiviral
agents should establish the utility of the hamster WEEV
infection model.
Results
Titration of WEEV in hamsters
Titration experiments revealed that hamsters were highly
susceptible to infection with WEEV. Disease progression was
rapid and mortality was high in this hamster model. A 100%
mortality rate was observed in all i.p. challenge groups with 10-
fold dilutions of stock from 106.5 down to 103.5 CCID50, while
one animal survived in the lowest (103.5 CCID50) dose
administered via i.n. inoculation (Table 1, experiment 1). A
60–80% mortality rate occurred in subsequent dilutions down
to 101.5 CCID50 with animals administered by i.p. injection
(Table 1, experiment 2). Mean day to death (MDD) appeared to
be dose responsive, with shorter times tending to be in animals
challenged with higher doses of virus. In the second titration
study, weight gain was recorded, and weight change betweenTable 1











1 106.5 i.n. 0/5 3.0±0.0 N/D
105.5 i.n. 0/5 3.4±0.9 N/D
104.5 i.n. 1/5 3.0±0.0 N/D
106.5 i.p. 0/5 3.0±0.0 N/D
105.5 i.p. 0/5 3.3±0.6 N/D
104.5 i.p. 0/5 4.0±0.0 N/D
2 103.5 i.p. 0/5 4.8±1.1 −1.2±7.0
102.5 i.p. 2/5 4.7±0.6 3.6±5.9
101.5 i.p. 1/5 5.0±0.0 5.8±2.6
Sham-
infected
i.p. 3/3 >21±0.0 8.0±4.4
a 50% cell culture infectious doses in 0.1 ml inoculation volume.
b Number of animals alive on day 21 per total challenged with virus.
c Mean day to death±standard deviation.
d Mean weight change between −24 h and 4 days post-virus inoculation.−24 h and 4 dpi was lower in animals infected with higher doses
of WEEV, but this difference in weight was not statistically
significant from weight gain in sham-infected controls (Table
1). A 101.5 CCID50 dose of virus was selected for use in studies
characterizing the model and in experiments evaluating antiviral
compounds because infection with this dose resulted in 80%
mortality.Fig. 2. Weight change of golden Syrian hamsters challenged with WEEV
(*P<0.05 as compared with sham-infected controls).
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Tissue samples were taken from selected animals challenged
i.p. with WEEVeach day after challenge to determine the time-
course of disease in hamsters. WEEV titers were significantly
elevated in tissues from infected hamsters, with peak titers in
brain, liver, and spleen on 4 dpi, while serum titers peaked 2 dpi
(Fig. 1). Brain virus titers were the highest, with a mean peak
titer of 8.6±1.5 log10 CCID50/g tissue. Weight gain was
significantly lower on 3, 4, and 5 dpi in hamsters challenged
with WEEV as compared with sham infection (Fig. 2).
In order to determine possible cell types in the brain that are
infected with WEEV, brain sections from 5 dpi necropsies were
double-stained for WEEVand one of two cell specific markers,
neuron specific enolase (NSE) or glial fibrillary acidic protein
(GFAP). WEEV-specific staining was observed in the cerebral
cortex and midbrain of infected animals. No specific staining
was observed in uninfected control brains. Neurons were the
cell type found to be most commonly infected with the virus,
and staining with NSE clearly co-localized with WEEV staining
(Fig. 3, arrow). Brain sections from animals infected with
WEEV had altered staining as compared with sections from
uninfected animals. These alterations were repeatedly observedFig. 3. Immunofluorescent localization of anti-WEEVand NSE in the brain tissue of
and B, E, and H show the WEEVexpression on the cerebral cortex and midbrain of u
the entire neuron with axons and dendrites (A, arrowhead), whereas infected hamsters
of WEEV with NSE. Scale bar=20 μm.to include a lack of NSE staining in the dendrites and axons of
infected neurons as compared with normal staining in neurons
from uninfected animals. NSE staining of infected neurons was
restricted to the cell body. WEEV staining was not found to co-
localize with GFAP staining and neuronal morphological
aberrations or pathology of brain sections was not apparent in
hematoxylin and eosin-stained sections from infected animals
(data not shown).
Treatment of WEEV infection
Pre-treatment with interferon alfacon-1 or Ampligen® 4 h
prior to virus challenge resulted in 100% survival of infected
animals. Weight gain was observed in infected animals treated
with either interferon alfacon-1 or Ampligen®; this was similar
to weight gain in sham-infected controls (Table 2). There was
no sign of toxicity in drug treatment groups as measured by
weight loss and mortality, and all sham-infected toxicity
controls appeared healthy and gained weight.
There was a highly significant (P<0.001) reduction in day 4
brain virus titer in animals treated with interferon alfacon-1,
where virus was reduced to below the limits of detection (Table
2). Ampligen® was also effective in significantly (P<0.01)uninfected (A–C) and infected (D–I) hamsters. A, D, and G show NSE staining
ninfected and infected hamster. NSE expression on the uninfected hamster stains
did not express NSE in those areas. Arrows (D–F) show the clear co-localization
Table 2
Effect of interferon alfacon-1 or Ampligen® on disease parameters of hamsters infected with western equine encephalitis virus
Treatment Dosage Treatment schedule Toxicity controls Infected, treated
Alive/total Mean weight
change (g) a




Interferon alfacon-1 5 μg/kg/day −4 h to 6 dpi, qd, i.p. 3/3 7.3 25/25⁎ >21±0.0⁎ 7.5 <3.6±0.0⁎
Ampligen® 3.2 mg/kg/injection −4 h and 2 dpi, i.p. 3/3 7.0 15/15⁎ >21±0.0⁎ 10.0 4.3±1.3**
Saline – −4 h to 6 dpi, qd, i.p. 3/3 8.0 9/40 5.5±1.1 2.0 8.1±1.8
⁎P<0.001, ⁎⁎P<0.01 as compared with placebo-treated, infected controls.
a Mean weight change between −24 h and 4 days after start of treatment.
b Data taken from 3 different experiments, data for interferon alfacon-1 from 2 experiments and Ampligen® treatment from 1 experiment, and saline placebo data are
combined placebo treatment from all 3 studies.
c Mean day to death of animals dying up to 21 days after virus challenge.
d Log10 CCID50/g tissue±SD virus from samples taken 4 days after virus inoculation.
457J.G. Julander et al. / Virology 360 (2007) 454–460reducing virus titer in the brain, although virus was detected in 3
out of 5 animals with a mean titer of 4.3±1.3 log10 CCID50/g
tissue (Table 2). The mean brain virus titer in placebo-treated,
infected controls was 8.1±1.8 log10 CCID50/g tissue.
Discussion
Hamsters were highly susceptible to WEEV infection when
challenged via i.p. or i.n. routes. A high mortality rate was
associated with a relatively small virus inoculum, which is
similar to infection in seen previously in hamsters as well as in
gerbils (Zlotnick et al., 1972; Hayles, 1972). A dose of 101.5
CCID50 was chosen as a dose for antiviral studies due to the
longer mean day to death, which allows more time for data
collection but is lethal enough to determine significance in
treatment studies. Previous work with hamsters has focused on
immunological clearance of virus and virulence studies
(Jahrling, 1976; Jahrling et al., 1983). The present study
represents the first use of hamsters as a model for the treatment
of WEEV disease. In general, >3-week-old mice are more
susceptible to intracranial or i.n. WEEV challenge and are less
susceptible to subcutaneous or i.p. challenge, which generally
yields approximately 50% mortality regardless of virus
concentration (Hardy et al., 1997; Liu et al., 1970). The
California strain of WEEV used in this study was also used in
mouse titration experiments conducted in our laboratory, and
variable mortality rates from experiment to experiment between
40 and 60% were observed with 103.5 to 105.5 CCID50
challenge doses (data not shown). Hamsters have also been
shown to be suitable animal models for other viral encephalitis
infections and often show better disease parameters and
susceptibility as compared with mouse models (Georges-
Courbot et al., 2006; Morrey et al., 2004a, 2004b). Yellow
fever virus (YFV) causes encephalitis in a mouse model, but in
hamsters causes a viscerotropic disease similar to the natural
disease in primates and man (Liu and Chambers, 2001; Tesh et
al., 2001). Due to the increased susceptibility of hamsters to
peripheral infection with the California strain of WEEV as
compared with mice, it appears that hamsters will serve as a
more robust model for antiviral studies.
Weight loss was observed in animals infected with higher
concentrations of WEEV. At lower viral challenges, the animalsdid not gain or lose weight; however, there was a statistically
significant difference in weight change between WEEV-
infected and sham-infected hamsters as seen in antiviral
experiments. Weight change between −24 h and 4 dpi appears
to serve as a useful parameter in evaluating the efficacy of
investigational antiviral compounds against WEE disease.
This encephalitic virus infected groups of neurons in the
cerebral cortex and in areas of midbrain. Similar results were
seen in cynomolgus macaques infected intranasally with
WEEV, where viral antigen was detected by immunohisto-
chemistry (IHC) in the brain, specifically in neurons, microglia,
and Purkinje cells (Reed et al., 2005). This also correlates with
previous studies involving an attenuated variant of eastern
equine encephalitis virus (EEEV), a closely related alphavirus,
where neuronal infection was observed in infected hamsters
(Dremov et al., 1978). The lack of staining in dendrites and
axons of the cerebral cortex and midbrain of infected hamsters
suggested viral induced changes. WEEV staining did not co-
localize with GFAP staining, indicating that astrocytes did not
produce adequate levels of antigen to be detected by IHC in
hamsters. It is interesting that viral antigen was not detected by
IHC in astrocytes since the closely related Venezuelan equine
encephalitis virus (VEEV) has been shown to infect primary
astrocytes (Schoneboom et al., 1999). In human cases of EEEV,
parykarion and dendrites of neurons were positive for EEE
antigen, and mature extracellular virus as well as some
morphological evidence for infection was observed (Garen et
al., 1999; Kim et al., 1985). West Nile virus, an encephalitic
flavivirus, was also found to infect neurons, but not astrocytes
in hamster and mouse models of infection (Shrestha et al., 2003;
Morrey et al., in press). From these results, it would appear that
WEEV primarily infects neurons and does not produce
detectable antigen levels in astrocytes in this hamster model.
Pathology of other organs and further characterization of
disease pathology are currently under investigation.
It is not surprising that interferon alfacon-1 was effective in
the treatment of WEEV if delivered before viral challenge as
this compound is effective in hamster models of Pichindae and
West Nile virus infections (Gowen et al., 2005; Morrey et al.,
2004a) and is highly inhibitory to WEEV in vitro (unpublished
data). Poly ICLC, another double-stranded RNA, has been
shown to be effective in the treatment of respiratory infection
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material, Ampligen®, used in the present study was very
effective in preventing disease in this hamster model when
injected 4 h before and 2 days after virus inoculation. While
these compounds work well when administered prophylacti-
cally, it is important that treatments for viral encephalitides are
effective therapeutically and show efficacy when given after the
development of clinical disease signs, which is the subject of
future studies. This model should be useful in determining
antiviral compounds that are efficacious in treating WEEVafter
clinical signs are apparent.
One negative aspect of this model is the short mean day to
death observed in infected hamsters, which allows only a small
therapeutic window. Another factor to be considered is the
greater amount of antiviral compounds necessary for treating
hamsters as compared with amounts needed to treat mice. From
these studies, it appears as if the hamster may serve effectively




Female Syrian golden hamsters weighing between 100
and 110 g were obtained from Charles River Laboratories
(Wilmington, MA). They were randomly assigned to cages and
individually marked with eartags. Hamsters were fed standard
rodent chow and tap water ad libitum and quarantined 48 h prior
to use.
Western equine encephalitis virus (WEEV)
WEEV (California strain, VR-70) was obtained from the
American Type Culture Collection (Manassas, VA) and used
after 3 passages in Vero cells. Stock virus was diluted 10− 5
(101.5 50% cell culture infectious doses [CCID50]/0.1 ml), and
hamsters were inoculated intraperitoneally (i.p.) with this
dilution. All work with this virus was performed in the
Biosafety Level 3 (BL-3) area of the AAALAC-accredited
Laboratory Animal Research Center (LARC) at Utah State
University (USU).
Test materials
Interferon alfacon-1 was obtained as a 30 mg/ml solution
from Intermune (Brisbane, CA). It was diluted in physiological
saline and stored at 4 °C until use. Ampligen® was provided by
Hemispherx Biopharma (Philadelphia, PA) as a 2.4 mg/ml
solution. The compound was stored at −20 °C until use.
Tissue virus titer determination
The virus titers in organs and serum were assayed using an
infectious cell culture assay where a specific volume of organ
tissue homogenate or serum was serially diluted and added to a
monolayer of Vero cells in a 96-well flat-bottomed microplate.Three days later, virus-induced cytopathic effect (CPE) was
used to identify the infectious virus end-point. Four replicates
were used for each sample.
Immunohistochemistry
At the time of necropsy, infected and uninfected animals
were perfused directly with PBS and 4% paraformaldehyde
during cardiac puncture. Slides made from paraffin embedded
samples were subjected to immunohistochemical protocols for
staining. Sections were immersed in diluted (1:10) DakoCyto-
mation Target Retrieval Solution (DakoCytomation Inc,
Carpinteria, CA) in distilled water and boiled in microwave
for 4 cycles of 1 min or boiled at 125 °C for 4 min in decloaking
chamber (Bio-care Medical, Walnut Creek CA). Sections were
permeabilized with 0.5% Triton X 100 in PBS for 5 min and
blocked using 10% normal goat serum in 0.2% Triton X 100 in
PBS blocking solution. Slides were simultaneously incubated
with mouse anti-WEEV (Chemicon, Temecula, CA), polyclonal
anti-neuron specific enolase (NSE), and polyclonal glial
fibrillary acidic protein (GFAP) (Chemicon, Temecula, CA)
primary monoclonal antibodies (mAb) diluted in 5% normal
goat serum and 0.2% Triton X 100 in PBS for 2 h. After
washing with PBS, slides were incubated with diluted Alexa-
fluor 568 goat anti-mouse IgG and Alexa-fluor 488 goat anti-
rabbit IgG secondary antibodies (Molecular Probes, Eugene,
OR) (1:200). The slides were washed and mounted with
VECTASHIELD mounting medium (Vector Laboratories,
Burlingame, CA). Stained slides were visualized using a
Nikon Eclipse TE300 microscope (Nikon) attached with
Lambda DG4 (Sutter Instrument Company, Novato, CA) and
a Bio-Rad MRC 1024 confocal microscope (Bio-Rad, Hercules,
CA). Control and experimental images were collected and
processed using the same instrument settings. Sections, stained
with hematoxylin and eosin, were observed to determine if
morphology of infected animals was altered.
Experimental design
A titration experiment was initially conducted to determine
an effective challenge dose for WEEV infection. Groups of
hamsters were challenged by i.p. or intranasal (i.n.) inoculation
with 10-fold dilutions of virus stock from 106.5 to 104.5 CCID50.
Mortality was observed for 21 days after virus challenge, and
weight change was recorded −24 h and 4 days post-virus
exposure. An additional titration experiment, from 103.5 to 101.5
CCID50 using i.p. inoculation, was conducted to achieve a
higher dynamic range. Weights of each animal were taken as
above, and weight change was calculated. Mortality was
observed for 21 days.
For the time-course experiment, tissue samples and weights
were taken from 10 hamsters on each day after virus challenge.
Samples were titered for virus by infectious cell culture assay,
and blood parameters, including PCV and WBC count, were
measured.
For evaluation of interferon alfacon-1 and Ampligen®,
animals were randomly assigned to treatment or control groups,
459J.G. Julander et al. / Virology 360 (2007) 454–460individually identified, and weighed. Animals in the Ampligen®
treatment group were treated with 3.2 mg/kg/day on −4 h and 2
dpi by i.p. injection. Interferon alfacon-1 was given i.p. once
daily, beginning −4 h and continuing through 8 dpi at a dose of
5 μg/kg/day. Each animal was challenged i.p. with 101.5 CCID50
of WEEVor sham-infected with dilution media. Brain samples
were taken at necropsy from 5 to 10 animals from each group on
4 days post-virus inoculation (dpi) and assayed for virus titer.
Ten hamsters were left in each group to measure survival daily
through 21 days. Hamsters were weighed on 4 dpi.
Statistical analysis
Survival data were analyzed using the Wilcoxon log-rank
survival analysis (JMP™ Software, The Statistical Discovery
Software, SAS Institute, Inc). All other statistical analyses were
done using one-way Students t-test.
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